The AIBN has the knowledge and infrastructure to ensure Australia can develop and deliver clinical-grade vaccines whenever, and wherever, they are needed.
As the biggest supplier of mRNA vaccines and therapies for research in Australia, the AIBN’s BASE facility is well-positioned to lead the world in mRNA translation for biotechnology firms.
AdvanCell is an Australian-based clinical-stage radiopharmaceutical company that is developing a range of novel therapies to boost cancer survival rates and improve patients’ quality of life.
Researchers at the AIBN are using synthetic biology to help the world’s biggest industries transition to net zero in a cutting-edge, Australian-first facility called the Biosustainability Hub.
AIBN researchers are working on ways to improve the efficiency of biofuel and chemical manufacture while recycling waste carbon – by better understanding the gene function of bacteria.
A pivotal collaboration between AIBN, the Queensland Government, Boeing, GE, Mackay Sugar Ltd and IOR Energy, has seen the development of an advanced new aviation biofuel made from sugarcane.
